Posted by Michael Wonder on 29 Nov 2016
Cancer immunology community seeks better end points
29 November 2016 - Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
